Last reviewed · How we verify
Cohort B1: Lu AE58054 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Cohort B1: Lu AE58054 (Cohort B1: Lu AE58054) — H. Lundbeck A/S.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cohort B1: Lu AE58054 TARGET | Cohort B1: Lu AE58054 | H. Lundbeck A/S | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cohort B1: Lu AE58054 CI watch — RSS
- Cohort B1: Lu AE58054 CI watch — Atom
- Cohort B1: Lu AE58054 CI watch — JSON
- Cohort B1: Lu AE58054 alone — RSS
Cite this brief
Drug Landscape (2026). Cohort B1: Lu AE58054 — Competitive Intelligence Brief. https://druglandscape.com/ci/cohort-b1-lu-ae58054. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab